About
Novartis Venture Fund is the corporate venture capital arm of Novartis, founded in 1996 to invest in innovative life science companies developing novel therapeutics and platforms that address unmet patient needs. Based primarily in Basel, Switzerland with a significant presence in Cambridge, Massachusetts, the fund manages over USD 750 million in committed capital and has made 356 to 367 cumulative investments across North America and Europe. The fund's investment thesis focuses on companies working in biotechnology, biopharmaceuticals, diagnostics, and healthcare technology at seed through later-stage rounds. NVF typically deploys checks ranging from USD 5 to 10 million as its sweet spot, with the flexibility to invest as little as USD 100,000 to initiate engagement and up to USD 25 million per company, anticipating total lifetime investments of USD 30 to 50 million per portfolio company. The fund has demonstrated particular strength in Series A investments, having made 65 Series A commitments with an average round size of USD 29.1 million, alongside 40 Series B investments averaging USD 41.4 million and 10 seed-stage investments averaging USD 24.5 million. Novartis Venture Fund operates with a hands-on investment approach, taking board seats and actively contributing to management strategy and clinical development. The fund's portfolio spans over 40 active companies with a track record of 99 portfolio exits. Entrepreneurs gain access not only to capital but also to the operational expertise, clinical development knowledge, and market access of the Novartis organization. The team comprises professionals with proven expertise in drug development, regulatory pathways, and therapeutic commercialization, positioned to provide strategic support beyond traditional venture capital involvement.